🏛️ Verified NIH Record • Updated 2026-03-04
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis (NCT04991116)
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Sun Pharmaceutical Industries Limited
🩺 Plain-English Summary (8th-Grade Level)
An open label phase 3 study
Who can join: Review the eligibility criteria below.
Location: Sunpharma site no 50 — Dothan, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (99 Sites)
Showing the first 25 of 99 sites.
- Sunpharma site no 50 — Dothan, Alabama
- Sunpharma site no 80 — Gilbert, Arizona
- Sunpharma site no 65 — Mesa, Arizona
- Sunpharma site no 105 — Phoenix, Arizona
- Sunpharma site no. 30 — Covina, California
- Sunpharma site no 110 — Encino, California
- Sunpharma site no. 17 — Fountain Valley, California
- Sunpharma site no. 15 — Thousand Oaks, California
- Sunpharma site no 113 — Avon Park, Florida
- Sunpharma site no. 21 — Clearwater, Florida
- Sunpharma site no. 02 — Hialeah, Florida
- Sunpharma site no 71 — Kissimmee, Florida
- Sunpharma site no 107 — Margate, Florida
- Sunpharma site no. 05 — New Port Richey, Florida
- Sunpharma site no 32 — Ocoee, Florida
- SunPharma Site no 22 — Tamarac, Florida
- Sunpharma site no 52 — Gainesville, Georgia
- Sunpharma site no 51 — Orland Park, Illinois
- Sunpharma site no 49 — Schaumburg, Illinois
- Sunpharma site no 47 — Skokie, Illinois
- Sunpharma site no. 20 — Wichita, Kansas
- Sunpharma site no. 14 — Springfield, Missouri
- Sunpharma site no 104 — St Louis, Missouri
- Sunpharma site no 48 — Kalispell, Montana
- Sunpharma Site no 27 — Lincoln, Nebraska
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriatic Arthritis
- A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs — Gilbert, Arizona
- Psoriatic Arthritis D2P Screening — Philadelphia, Pennsylvania
- Apremilast Pregnancy Exposure Registry — La Jolla, California
- Psorcast Mobile Study — Seattle, Washington
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy — Anniston, Alabama
Explore by condition: All Psoriatic Arthritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.